Kalamazoo Resources Limited (KZR)
CXA 
Summary
Kezar Life Sciences (KZR) Upgraded to Buy: What Does It Mean for the Stock?
Kezar Life Sciences (KZR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Kezar Life Sciences, Inc. (KZR) PORTOLA Topline Phase 2a Results in Autoimmune Hepatitis Conference Call (Transcript)
Kezar Life Sciences, Inc. (NASDAQ:KZR ) PORTOLA Topline Phase 2a Results in Autoimmune Hepatitis Conference Call March 25, 2025 8:00 AM ET Company Participants Chris Kirk - Chief Executive Officer & Co-Founder Dr. Craig Lammert - Principal Investigator of PORTOLA Study Gideon Hirschfield - Professor University of Toronto, Autoimmune Liver Disease Research Conference Call Participants Matt Phipps - William Blair Divya Rao - TD Cowen Maury Raycroft - Jefferies Derek Archila - Wells Fargo Mitchell Kapoor - H.C. Wainwright Operator Good day, everyone.
What Makes Kezar Life Sciences (KZR) a New Buy Stock
Kezar Life Sciences (KZR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Kalamazoo Resources Limited (KZR) FAQ
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Kalamazoo Resources Limited ever had a stock split?
Kalamazoo Resources Limited Profile
| Biotechnology Industry | Healthcare Sector | Christopher J. Kirk CEO | CXA Exchange | US49372L2097 ISIN |
| US Country | 55 Employees | - Last Dividend | 30 Oct 2024 Last Split | 21 Jun 2018 IPO Date |
Overview
Kezar Life Sciences, Inc. is a clinical-stage biotechnology firm actively engaged in the innovation and development of small molecule therapeutics. Founded in 2015 and located in South San Francisco, California, the company focuses its research on addressing the unmet medical needs of patients suffering from immune-mediated diseases and cancer. By harnessing its expertise in novel therapeutic development, Kezar Life Sciences aims to improve the quality of life for patients across the United States through groundbreaking medical advancements.
Products and Services
-
Zetomipzomib (KZR-616)
As the flagship product candidate of Kezar Life Sciences, Zetomipzomib represents a revolutionary approach in treating autoimmune diseases. This selective immunoproteasome inhibitor is undergoing rigorous clinical trials across various stages and indications. For patients battling lupus nephritis, dermatomyositis, and polymyositis, Zetomipzomib is in Phase 2b clinical trials. Additionally, it is in Phase 1b clinical trials for those suffering from systemic lupus erythematosus and has successfully completed Phase 2a clinical trials for lupus nephritis. This targeted treatment aims to offer a new beacon of hope for individuals facing these challenging conditions.
-
KZR-261
Kezar Life Sciences’ preclinical developments include KZR-261, a pioneering product that positions itself as a first-in-class protein secretion inhibitor. This novel compound is designed to combat tumors that have developed resistance to conventional chemotherapy treatments. By targeting the protein secretion pathways crucial for tumor growth and survival, KZR-261 has the potential to redefine cancer treatment paradigms and offer new hope to patients with hard-to-treat cancers.
Contact Information
